Krystal Biotech KRYS
NASDAQ KRYS
$322.28 -3.03 (-0.93%)
At close: Oct 2, 2026 · 4:00 PM EDT

Krystal Biotech (KRYS) Gains from Sales and Divestitures (2019 - 2023)

Updated

Krystal Biotech (KRYS) posted Gains from Sales and Divestitures of $100 million for FY2023.

Analysis

Krystal Biotech (KRYS) Gains from Sales and Divestitures (2019 - 2023) Analysis & Trends

  • The FY2023 figure stands as the lowest annual Gains from Sales and Divestitures since FY2020.
  • Business Quant data shows KRYS's Gains from Sales and Divestitures at -$33,000 in FY2020 and -$67,000 in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Krystal Biotech 9.54 Bn 6.31 Bn 112.79 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 100.00 Mn
Dec 31, 2022 22,000.00
Sep 30, 2020 -30,000.00
Dec 31, 2019 -13,000.00
API Access

Krystal Biotech Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=KRYS&period=max&api_key=YOUR_API_KEY